Enrique Grande, ENETS Conference 2021: Clinical Trials in Europe
We were delighted to talk to Dr Enrique Grande (MD Anderson Cancer Center, Madrid) about clinical trial development of neuroendocrine tumours. The abstract ‘Clinical Trials in Europe’ was presented at the virtual 18th Annual European Neuroendocrine Tumor Society (ENETS) Conference 2021.
- Could you give us a brief overview of the different approaches to the treatment of neuroendocrine tumours (NETs) that are currently in advanced clinical trial development in Europe? (0:12-0:55)
- What has been the most exciting clinical trial data to emerge in the last year? (0:56- 2:05)
- What are the key take-home messages of your presentation? (2:06-3:21)
Disclosures: Honoraria for speaker engagements, advisory roles or funding of continuous medical education: Adacap, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Eisai, Eusa Pharma, Genetracer, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, Tecnofarma, Thermo Fisher Scientific. Research Grants: Astellas, Astra Zeneca, IPSEN, Lexicon, MTEM/Threshold, Nanostring Technologies, Pfizer, Roche. Leadership roles in medical societies: ENETS, GETNE and GETHI. Private Healthcare provider: MD Anderson Cancer Center Madrid (workplace). Commercial Medical Education provider: Universidad Europea de Madrid (UEM), Universidad CEU Cardenal Herrera, Universidad Rey Juan Carlos, Oncinfo
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ENETS 2021 (Virtual).
Share this Video
Related Videos In Endocrine Oncology
Ashley Grossman: Research highlights from 2022 in neuroendocrine tumours
New exciting therapies for neuroendocrine tumours include the introduction of RET inhibitors for medullary thyroid cancer and belzutifan for metastatic pancreatic neuroendocrine tumours. We were delighted to speak with our editorial board member Prof. Ashley Grossman (University of Oxford, Oxford, UK) around this year’s research highlights in these topics and what to look out for […]
Camilo Jimenez, ENDO 2021: The Role of Tumour Biomarkers in the use of I-131MIBG
It was a pleasure to talk to Professor Camilo Jimenez (The University of Texas MD Anderson Cancer Center, Houston, TX) around biochemical tumour markers in the use of I-131-labeled MIBG for pheochromocytoma and paraganglioma. ‘Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and […]
Camilo Jimenez, ENDO 2021: Tumour Biomarkers in the use of I-131MIBG for Pheochromocytoma and Paraganglioma
It was a pleasure to talk to Professor Camilo Jimenez (The University of Texas MD Anderson Cancer Center, Houston, TX) around biochemical tumour markers in the use of I-131-labeled MIBG in pheochromocytoma and paraganglioma. ‘Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!